

Vitamin D During Pregnancy and Maternal, Neonatal and Infant Health Outcomes: A Systematic Review and Meta-analysis

Andrew Thorne-Lyman,^a Wafaie W. Fawzi^{a,b,c}

Departments of ^aNutrition, ^bEpidemiology and ^cGlobal Health and Population, Harvard School of Public Health, Boston, MA, USA

Abstract

Vitamin D has well-defined classical functions related to calcium metabolism and bone health but also has non-classical effects that may influence other aspects of health. There has been considerable recent interest in the role of vitamin D on outcomes related to pregnancy and young child health but few efforts have been made to systematically consolidate this evidence to inform the research and policy agenda for low-income countries. A systematic review was undertaken to identify intervention and observational studies of vitamin D supplementation, intake or status (25-hydroxy-vitamin D) during pregnancy on perinatal and infant health outcomes. Data from trials and observational studies isolating the effect of vitamin D supplementation and intake were extracted and study quality was evaluated. Meta-analysis was used to pool effect estimates. We identified five randomised trials with outcomes of relevance to our review. All had small sample size and dosage amount, duration and frequency varied as did the ability to correct deficiency. Pooled analysis of trials using fixed-effects models suggested protective effects of supplementation on low birthweight (three trials, risk ratio (RR) = 0.40 [95% confidence interval (CI) 0.23, 0.71]) and non-significant but suggestive effects of daily supplementation on small-for-gestational age (two trials, RR = 0.67 [0.40, 1.11]). No effect on preterm delivery (<37 weeks) was evident (two trials, RR = 0.77 [0.35, 1.66]). Little evidence from trials exists to evaluate the effect of vitamin D supplementation during pregnancy on maternal, perinatal or infant health outcomes. Based on both trials and observational studies, we recommend that future research explore small-for-gestational age, preterm delivery, pre-eclampsia, and maternal and childhood infections, as outcomes of interest. Trials should focus on populations with a high prevalence of vitamin D deficiency, explore the relevance of timing of supplementation, and the dosage used in such trials should be sufficient to correct deficiency.

Keywords: *Vitamin D, birth outcomes, child health, developing countries, perinatal, growth.*

There is evidence of early interest in the relationship between vitamin D status and perinatal health outcomes. 'Rachitic pelvis' was noted as a common obstetric complication in the early 20th century, and may have contributed to the development of caesarian section birthing procedures.¹ In the 1930s, Green and Mellanby speculated that vitamin D had little 'anti-infective' activity but 'might prove of significance in connexion with other obstetric difficulties, such as uterine inertia'.² Associations between childhood rickets, sunlight or cod-liver oil and risk of respiratory infections such as tuberculosis and pneumonia were recognised a century ago, although it has only been in recent years that the effects of vitamin D on immunity

have been revisited and the underlying mechanisms behind its putative effects have started to become more clear.³

Vitamin D can be synthesised in the skin through exposure to ultraviolet (UV) light or can be obtained through dietary intake. Sunlight exposure is often the major influence on vitamin D status and is influenced by skin colour, latitude, season, as well as life style and cultural practices. In comparison, diet is often thought to exert a minor influence on vitamin D status although consumption of supplements can strongly influence status.^{4,5}

Globally, it has been estimated that a billion people may be affected by vitamin D deficiency or insufficiency.⁶ Generally, populations from countries near the equator (particularly agrarian and nomadic populations) are thought to have sufficient exposure to UV wavelengths required for optimal vitamin D status, and this has indeed been the case in some surveys.^{4,7}

Correspondence: Andrew Thorne-Lyman, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Building II Room 320, Boston, MA 02115, USA.
E-mail: athornel@hsph.harvard.edu

Yet, childhood rickets, a condition caused vitamin D and/or calcium deficiency, has long been noted in certain equatorial populations, particularly those in which head covering or spending time indoors is common.⁴ Recent studies in Ethiopia and India have also found that more than 80% and 66% of pregnant women suffered from vitamin D deficiency using a cut-off of <50 nmol/L 25(OH)D, indicating the need for more research on potential adverse effects of deficiency and benefits of supplementation in developing country contexts.^{8,9}

Metabolism of vitamin D during pregnancy and maternal-fetal links

Once ingested or produced by the body, vitamin D₃ is transported to the liver for hydroxylation to 25(OH)D, the main circulating form of vitamin D and best measure of vitamin D status, and then to the kidney where the active hormonal form of vitamin D, 1,25(OH)₂D, is produced. Maternal 25(OH)D is thought to freely cross the human placenta as it does in rats.¹⁰ The placenta expresses vitamin D receptors and also produces the enzyme CYP27B1 to convert 25(OH)D to its active form.¹¹

The most widely appreciated role of vitamin D in the human body is to maintain normal levels of calcium and phosphate in the blood, which in turn facilitate other essential processes such as bone mineralisation, contraction of muscles, nervous system activities and cellular function.¹² Adequate vitamin D status is critically important for the neonate, with neonatal hypocalcaemia and rickets being major consequences of deficiency.¹⁰ In areas where vitamin D deficiency is endemic, rickets may be diagnosed soon after birth.¹⁰ In general, breastmilk is thought to be a relatively poor source of vitamin D, thus maternal vitamin D status during pregnancy is important for vitamin D status of the child during early infancy.^{10,13,14}

There are a number of plausible biological pathways through which vitamin D could influence placental, fetal and maternal health or growth during pregnancy. Vitamin D has important immune-modulating properties of vitamin D, which may help to establish a proper maternal immune response to the placenta.^{15–17} It also regulates key target genes associated with proper implantation of the placenta.¹⁸ Vitamin D has a direct role in the production of antimicrobial peptides such as cathelicidin, which are produced upon activation of up-regulated vitamin D receptors, require 25(OH)D as

a substrate for production, and may play an important role in preventing infection during pregnancy or early childhood.^{3,19–22} In its active form, vitamin D regulates expression of human chorionic gonadotropin in syncytiotrophoblasts and stimulates production of sex steroids.^{23,24} *In vitro* and animal studies have also suggested that vitamin D has important roles in glucose and insulin metabolism, which may affect availability of energy to the fetus.^{16,25,26} Vitamin D also influences musculo-skeletal growth.^{27–30}

Requirements for vitamin D

The recommended daily allowance of vitamin D for women in the US aged 19–50 years, including during pregnancy, was recently established at 600 international units (IU) per day.³¹ This recommendation was based on the amount of intake necessary to sustain blood levels of 25(OH)D above 50 nmol/L for populations with minimal sunlight exposure and was developed solely based on outcomes related to skeletal health.³¹ This recommendation was contentious as many researchers have argued that insufficiency should be defined at thresholds of 75 nmol/L or even higher, which would require a much higher intake to reach.^{32,33}

A number of recent reviews have covered a rapidly growing body of literature on vitamin D during pregnancy,^{4,16,34–37} although few have taken a systematic approach³⁵ and only a couple have focused on the implications for low-income country settings.^{4,38} To address this gap, we undertook a systematic review of the literature on vitamin D during pregnancy and perinatal and infant health outcomes.

Methods

The primary aim of our literature search was to identify epidemiological studies that isolated the effect of intake of vitamin D from supplements or diet on the outcomes presented in Table 1. Skeletal health-related outcomes such as bone mineralisation and rickets were not part of this review and have been detailed elsewhere.^{10,31,39} Recognising in advance that few supplementation trials had been published, we sought to also identify prospective observational studies with intake of vitamin D or maternal blood 25(OH)D levels during pregnancy as exposures. Using the search strings outlined in Table S1 we searched the NLM Pubmed database and Cochrane Library through June

Table 1. Primary outcomes covered by this review

-
1. Low birthweight due to intra-uterine growth restriction
 - 1a. Small-for-gestational age
 - 1b. Low birthweight
 - 1c. Mean birthweight
 - 1d. Weight gain during pregnancy
 - 1e. Mean heel-crown length at delivery
 2. Preterm birth
 - 2a. Preterm birth (<37 weeks)
 - 2b. Early preterm birth (<34 weeks)^a
 - 2c. Mean gestational age at delivery
 3. Neonatal growth, morbidity and mortality
 - 3a. Early infant mortality (first 6 weeks)^a
 4. Infant or child growth, morbidity and mortality
 - 4a. Mean weight^a
 - 4b. Mean height^a
 - 4c. Low weight-for-age^a
 - 4d. Low height-for-age^a
 - 4e. All-cause mortality^a
 - 4f. Mortality due to measles, diarrhoea, ALRI or malaria^a
 - 4g. Mother-to-child transmission of HIV^a
 - 4h. Morbidity (diarrhoea, measles, malaria, ALRI)^a
 5. Maternal morbidity and mortality
 - 5a. Mortality (all cause)^a
 - 5b. Mortality due to haemorrhage, sepsis or obstructed labour^a
 - 5c. Delivery complications (caesarian section)^a
 - 5d. Pre-eclampsia
-

^aIndicates outcomes for which outcomes from more than one study could not be extracted for meta-analysis.

ALRI, Acute lower respiratory infection.

2011 as well as the bibliographies of reviews and relevant studies.

An initial review of titles and abstracts was undertaken by one reviewer followed by an in-depth review of full papers that could not be initially excluded (AT-L). We excluded (1) non-human studies, (2) studies not in English, French or Spanish, (3) reviews, case reports and commentaries, (4) topics unrelated to the review, (5) studies that could not isolate the effects of vitamin D supplementation or intake, and (6) cross-sectional and non-prospective case-control studies. A modified version of the Child Health Epidemiology Reference Group's GRADE tool was used to evaluate intervention studies and observational studies of vitamin D intake for risk of bias, and those with a study quality of 'Very Low' were excluded. Authors of recent trials presenting clinical outcomes were requested to provide additional data on other outcomes of relevance to the meta-analysis.

Study data were extracted using a standard spreadsheet. Review Manager 5.1⁴⁰ was used to generate

pooled effect estimates for all outcomes with data from more than one eligible study. For studies with continuous outcomes we generated mean differences and for dichotomous outcomes we calculated relative risk or odds ratio estimates, each with 95% confidence intervals (CI). Inverse variance weights were used to generate pooled effect estimates with a fixed-effects model in absence of significant heterogeneity. Heterogeneity was explored through visual inspection of Forest plots as well as through I^2 values and χ^2 -tests for heterogeneity. In the presence of significant heterogeneity ($P < 0.10$), we used a random-effects model. For trials testing multiple intervention arms (of daily or bolus doses), we pooled data from intervention arms, calculated the pooled mean and standard deviation⁴¹ where appropriate, and also presented separate analysis for daily vs. bolus dosage. For observational studies, comparisons were made of extreme categories.


Results

Identification of studies

We identified 944 hits through our database searches and five additional studies through bibliographical searches (Figure 1). Five trials of vitamin D supplementation during pregnancy met our inclusion criteria, one of which did not provide sufficient data for inclusion in quantitative analysis,⁴² and one study was excluded that ranked 'Very Low' on GRADE criteria (Table 2 and Table S2).⁴³ Additional data were received from the authors of two recently published trials (personal communication with Dr Yu, November 2011 and Drs Hollis/Wagner, January 2012). Six observational studies of vitamin D intake were identified of which two^{44,45} ranked 'Very Low' on GRADE criteria (Table S3). We also found 13 studies with prospective assessment of 25(OH)D prior to birth outcomes (Table S4) and four studies in which pre-eclampsia was reported as an outcome (Table S5).

All but one trial⁴⁶ and four observational studies of 25(OH)D were conducted in high-income country settings, and most populations had either a presumed risk or high prevalence of deficiency at baseline (Table 1).^{9,47-50} Dosing approaches in the trials varied: two trials contained multiple intervention arms testing both daily supplementation (800 IU and 1000 IU D₂) and high single dose supplementation (200 000 IU) in the third trimester.^{42,51} One recent trial tested both

Figure 1. Study flow.



daily 2000 IU D₃ and daily 4000 IU D₃, the latter at the upper limit of the current US recommendations and a study in India tested the effects of two bolus doses of 600 000 IU.³¹

Vitamin D supplementation appeared to improve maternal 25(OH)D levels in all four trials with available data although mean attained levels at term in two trials indicated that the dosage tested was not sufficient to alleviate deficiency in much of the population (Table S6).^{42,51} In contrast, the results of trials by Hollis and Brooke indicated a substantial improvement in vitamin D status, and there is some speculation that the dose used in the latter trial may have been higher than reported.^{5,36,52}

Birthweight, low birthweight and crown–heel length at birth

The results of all meta-analyses are summarised in Table 3. Pooled analysis of all five trials with informa-

tion on mean birthweight suggested no significant overall effect (Figure S1), although significant heterogeneity was apparent ($I^2 = 70\%$, $P = 0.0009$) due largely to the divergent results of studies testing a large bolus dose the two. Pooled results of observational studies indicated a significant 52 g increase [3.5, 102] comparing the highest vs. lowest categories of intake (Figure S1). An observational study in New Zealand also found a significant 71 g birthweight difference across quartiles of intake noting low median intakes of 68 IU/day in the population although data were insufficient for pooling.⁵³

Pooled analysis of three trials revealed that supplementation led to a significant 60% reduction in the risk of low birthweight (Figure 2), and disaggregated analysis of bolus high dose trials also suggested a strong benefit [two trials, risk ratio (RR) = 0.25 [0.11, 0.61]] although daily supplementation trials did not show statistically significant benefit (two trials, RR = 0.56 [0.27, 1.13]) (Figure S2).

Table 2. Description of intervention studies of vitamin D supplementation and observational studies of vitamin D intake (including supplements) eligible for inclusion in meta-analyses

Study ID	Country and latitude ^a	Population	Intervention or exposure	Comments and GRADE assessment of risk of bias
Intervention studies				
Brooke (1980) ^{52,69,91}	UK (London) 51°N	Affluent Asian immigrants in the third trimester. Excluded preterm deliveries, congenital malformations and certain maternal illnesses. Mean 25(OH)D: 20.1 nmol/L at 28 weeks	Randomised to a daily dose of (1) 1000 IU vitamin D ₃ (n = 59) or (2) placebo (n = 67) provided from 28 to 32 weeks of gestation to delivery	Double-blind RCT. Small sample size GRADE: Moderate
Hollis (2011) ^{5b}	US (South Carolina) 34°N	Multi-ethnic population, mean age 27 years, women with pregnancy <16 weeks of gestation at enrolment. All participants received prenatal multivitamin/mineral supplement. Mean baseline 25(OH)D by group: 58.2–61.6 nmol/L	Randomised to daily dose of (1) 400 IU vitamin D ₃ (n = 111), (2) 2000 IU vitamin D ₃ (n = 122), (3) 4000 IU vitamin D ₃ (n = 117) provided from 12 to 16 weeks until delivery. Women with baseline 25(OH)D levels >100 nmol/L randomised to group 1 or 2	Double-blind RCT. Loss to follow-up, potential selection bias due to randomisation process. GRADE: Moderate
Mallet (1986) ⁵¹	France (North-west) 49°N	Caucasian population, mean age 25 years, analysis included at-term infants born at term during February and March. Mean maternal 25(OH)D in the unsupplemented group was 9.4 nmol/L	Random assignment to (1) 1000 IU vitamin D ₂ daily for last 3 months of pregnancy (n = 21), (2) one-time dose of 200 000 IU in the seventh month of gestation (n = 27), (3) no supplement (n = 29)	Randomised non-placebo controlled trial; unclear whether women were randomised into the control group. GRADE: Moderate
Mayra (1988) ⁴⁶	India (Rohtak) 28°N	Singleton pregnancies aged 22–35 years attending antenatal clinic of a medical college. Complications including pre-eclampsia, haemorrhage or premature delivery excluded. 25(OH)D levels not assessed	Random selection to (1) two doses of 600 000 IU vitamin D ₃ , one each in month 7 and 8 of pregnancy (n = 100), (2) no supplement (n = 100)	Randomised non-placebo controlled trial; method of randomisation unclear, no placebo, unclear dropout/number of exclusions. GRADE: Low
Yu (2009) ^{2b}	UK (London) 51°N	Multi-ethnic hospital population recruited at 27 weeks of gestation. Excluded women with pre-existing sarcoidosis, osteomalacia, renal dysfunction, tuberculosis. Median 25(OH)D = 25 nmol/L at 27 weeks	Random selection to (1) single oral dose of 200 000 IU vitamin D (n = 60), (2) daily supplementation with 800 IU vitamin D from 27 weeks to delivery (n = 60), (3) no treatment (n = 60)	Randomised non-placebo controlled trial. Small sample size, no placebo. GRADE: Moderate
Observational studies				
Haugen (2009) ⁷⁴	Norway (nationwide) 58°–71°N	23 423 nulliparous pregnant women from the Norwegian Mother and Child Cohort study with singleton births recruited at first ultrasound exam	FFQ used to assess intake of vitamin D for the first 4–5 months of pregnancy and supplement use assessed at week 30	Prospective cohort study. Supplement use validated with good correlation against reported use and biomarkers. Large sample size. GRADE: Moderate
Scholl (2009) ⁶³	US (Camden, New Jersey) 39°N	Multi-ethnic cohort, data from 2215 pregnancies enrolled at entry to prenatal care. Excluded those with serious non-obstetric problems	Dietary intake of vitamin D and supplement use assessed using three 24 h recalls	Large sample size, controlled for ethnicity, body mass index, energy intake, intake of key nutrients and gestational duration for birthweight. GRADE: Moderate
Camargo (2007) ⁶⁰	US (Massachusetts) 42°N	1194 mother–child pairs from Project Viva cohort. Excluded multiple gestations, non-English speakers, plans to move and gestational age >22 weeks at initial appointment	Dietary intake was collected using a validated semi-quantitative FFQ and intake from supplements was collected for the first and second trimesters	Large sample size, examination by quintiles of intake. Only presented unadjusted analysis for perinatal outcomes. GRADE: Low
Oken (2007) ⁸⁹	US (Massachusetts) 42°N	1178 women from the Project Viva cohort recruited after median 10.4 weeks of gestation. Excluded women with pre-existing hypertension	Same as Camargo (2007) ⁶⁰ above	Large sample size, examination by quintiles of intake. GRADE: Low

^a Approximate latitude estimated by authors.


^b Additional unpublished or in-press data were also provided by author.

IU, international units; RCT, randomised controlled trial; FFQ, Food Frequency Questionnaire.

Table 3. Summary of findings and overall assessment of quality of evidence for randomised trials and observational studies


Quality assessment					Summary of findings			
No. studies and study design	Heterogeneity of results?	Consistent size of effect?	Generalisable to population of interest?	Generalisable to intervention of interest?	Other sources of bias (e.g. major limitations in study design)	#	Statistical method	Effect estimate [95% CI]
Trials: Small-for-gestational age, overall quality of evidence grade = Low								
Two RCTs ^{42,52} (one with two arms)	Low ($I^2 = 0\%$), $P = 0.39$	Both protective	Both in the UK among deficient largely non-white populations	Similar dose (800 IU and 1000 IU daily); both in the third trimester	Both small studies	305	RR, IV Fixed effects	0.67 [0.40, 1.11]
Trials: Weight gain during the third trimester (g), overall quality of evidence grade = Low								
Two RCTs ⁶¹	High ($I^2 = 65\%$, $P = 0.09$)	Yes – both showed increased weight gain in vitamin D group	India, Asian immigrants in the UK	Both in the third trimester; one with daily 1000 IU vs. one with 600 000 IU at month 7 and 8	Both small studies	326	MD, IV Random effects	11.8 g/day [3.4, 20.2]
Trials and observational studies: mean birthweight, overall quality of evidence grade = Low								
1. Trials: five RCTs (three with two intervention arms) ^{5,42,46,51,52}	1. High ($I^2 = 70\%$, $P = 0.0009$); one arm decreased weight	Most trials null; one increased weight	All in deficient populations; one from India, remaining from high-income settings	Wide variety of doses tested ranging from 800 IU daily to 4000 IU daily and large bolus doses up to 2x 600 000 IU	Only two had blinded control groups; all small sample size; high or unclear dropout in two studies	932	MD, IV Random	58.1 [-63.9, 180.0]
2. Observational studies: two studies ^{60,63}	2. None ($I^2 = 0\%$, $P = 0.49$)					1497	MD, IV Fixed	52.7 [3.5, 101.8]
Trials: Low birthweight (<2.5 kg), overall quality of evidence grade = Low								
Three RCTs (one with two intervention arms) ^{42,46,52}	Low ($I^2 = 5\%$, $P = 0.35$)	RR ranged from 0.21 to 0.55 (only one significant)	One in India, others in London among Asian migrants and mixed population	Mix of daily supplementation (800–1000 IU) and bolus dosing at high doses, all in the third trimester	Only one study placebo controlled	507	RR (IV, Fixed, 95% CI)	0.40 [0.23, 0.71]
Trials: Crown-heel length at birth (cm), overall quality of evidence grade = Low								
Two RCTs ^{46,52}	High ($I^2 = 82\%$, $P = 0.02$)	One null, one with significantly greater weight gain	One in India, one among Asian immigrants to the UK	1000 IU D ₂ ; Bolus 600 000 IU at month 7 and 8	One unblinded	317	MD, IV Random effects	1.02 [-0.26, 2.30] cm
Trials: Preterm delivery (<37 weeks), overall quality of evidence grade = Low								
Two RCTs ^{5,42} (both had two intervention arms pooled here)	Moderate ($I^2 = 46\%$, $P = 0.17$)	Both null in opposite directions	Both in multi-ethnic populations in high-income countries	(1) 4000 or 2000 IU vs. 400 IU, (2) daily 800 or bolus 200 000 IU vs. nothing	One unblinded	529	RR, IV Fixed effects	0.77 [0.35, 1.66]
Trials and observational studies: mean gestational age at delivery (in weeks), overall quality of evidence grade = Low								
Two RCTs ^{5,42} with two intervention arms	Low ($I^2 = 7\%$, $P = 0.30$)	All null	All in high-income countries	Comparison of 4000/2000 IU vs. 400 IU and daily 800 IU vs. nothing	One unblinded; one observational study did not adjust for confounding	529	MD, IV	0.17 [-0.16, 0.51]
Two observational studies ^{60,65}	None ($I^2 = 0\%$, $P = 0.75$)					1497	Fixed effects	0.08 [-0.12, 0.28]
Observational studies: pre-eclampsia, overall quality of evidence grade = Very Low								
Two observational studies ^{74,89}	None ($I^2 = 0\%$, $P = 0.33$)	Both null	Both in high-income countries	One comparison of <200 vs. >800 IU; one based on continuous exposure		12 626	OR, IV Fixed effects	0.95 [0.86, 1.06]

CI, confidence interval; IU, international units; RCT, randomised controlled trial; RR, risk ratio, MD, mean difference, IV, inverse variance; OR, odds ratio.

Combined daily or bolus supplementation and SGA

(1) Daily 1000 IU D2 vs. placebo

(2) Intervention group pooled 800 IU/daily with bolus 200 000 IU group vs. unsupplemented

Combined daily or bolus supplementation and low birthweight

(1) Daily 1000 IU D2 vs. placebo

(2) Intervention group received 600 000 IU vitamin D3 at 7th and 8th month of gestation

(3) Intervention group pooled 800 IU/daily with bolus 200 000 IU group

Figure 2. Trials of vitamin D supplementation and risk of low birthweight and small-for-gestational age (SGA). IV, inverse variance; CI, confidence interval; IU, international units.


The majority of studies examining relationships between maternal vitamin D status and mean or low birthweight found no association.^{9,30,47,49,54,55} However, two large studies, one from the Netherlands and the other from Australia, both found significantly lower birthweight among infants born to women with vitamin D deficiency (using thresholds of <25 and 29 nmol/L).^{56,57} Another study from Australia found no overall effect of low maternal 25(OH)D levels (<28 nmol/L) on mean birthweight, yet effect modification was found by infant vitamin D receptor (*FokI*) genotype: offspring born to women in the with higher 25(OH)D levels were significantly heavier within the FF or Ff but not the ff genotypes.⁵⁸

Pooled analysis of two supplementation trials showed no significant difference in mean crown–heel length associated with supplementation (Figure S3). None of the observational studies we identified reported a significant association between maternal 25(OH)D status and crown–heel length at birth.^{9,30,47,54,55,57,59}

Small-for-gestational age and gestational weight gain


Pooled analyses indicated significantly greater average daily weight gain in the third trimester among women supplemented with vitamin D (two trials, 11.8 g/day [3.4, 20.2]) (Figure S4), and a non-statistically significant 33% decrease in the risk of small-for-gestational age (SGA) (Figure 2). However, an observational cohort study from Boston reported no difference in birthweight for gestational age by quartile of vitamin D intake in unadjusted analysis.⁶⁰

Prospective observational studies of vitamin D status and SGA have had mixed findings (Table S4). Two studies, one of HIV-positive women in Tanzania and another among pregnant adolescents in the UK, did not find statistically significant associations between maternal 25(OH)D levels and SGA.^{49,61} However, the largest study to date, from the Netherlands, found that the risk of SGA among vitamin

Daily or bolus supplementation and preterm delivery (< 37 weeks)

(1) Pooled 2000 IU and 4000 IU trial arms vs. 400 IU comparison

(2) Pooled daily 400 IU and bolus 200 000 IU arms vs. unsupplemented

Daily or bolus supplementation and mean gestational age at delivery (in weeks)

(1) Intervention group pooled 2000 IU/day and 4000 IU/day groups; comparison with 400 IU/day

(2) Intervention group pooled 800 IU/daily with bolus 200 000 IU group

Figure 3. Trials of vitamin D supplementation and risk of preterm delivery and mean duration of gestation. IV, inverse variance; CI, confidence interval; IU, international units.

D-deficient women [$25(\text{OH})\text{D} < 30 \text{ nmol/L}$] was nearly twice that of women with adequate status in multivariable adjusted models (adjusted odds ratio (OR) 1.9 [95% CI 1.4, 2.7]).⁵⁷ A recent nested case-control study from Pittsburgh found evidence of a U-shaped relationship between vitamin D status and SGA among white women in the study: those with serum $25(\text{OH})\text{D}$ levels less than 37.5 nmol/L had a 7.5-fold [95% CI 1.8, 31.9] higher risk of SGA compared with those with levels between 37.5 and 75 nmol and those with levels exceeding 75 nmol/L had a 2.1 times higher risk [1.2, 3.8].⁶² Effect modification by race was also evident as no statistically significant relationships between serum $25(\text{OH})\text{D}$ levels and SGA risk were observed among black women included in the study.

Preterm birth

No significant association was evident between vitamin D supplementation and preterm delivery (<37 weeks) or mean duration of gestation in pooled analyses (Figure 3, Figure S5), or in two observational

studies of intake of vitamin D and mean duration of gestation (Figure S6).^{5,42,60,63}

Two studies examined relationships with blood levels of $25(\text{OH})\text{D}$ during pregnancy and preterm birth. In Tanzania, no difference in risk of preterm birth (<37 weeks, $\text{RR} = 0.84$ [0.55–1.28]) or early preterm birth (<34 weeks, $\text{RR} = 0.77$ [0.50, 1.18]) was observed among HIV-positive women using a cut-off of 80 nmol/L .⁴⁹ Similarly, no difference in the third trimester $25(\text{OH})\text{D}$ levels was found for adolescents in the UK delivering preterm vs. normal gestational length babies.⁶¹

Observational studies with serum $25(\text{OH})\text{D}$ levels as an exposure did suggest longer gestational duration associated with higher $25(\text{OH})\text{D}$ levels. In the Netherlands, women with serum levels $>50 \text{ nmol/L}$ had a slightly longer gestational length of 40.2 weeks vs. 40.0 weeks vs. women in two categories of lower intake ($P < 0.001$).⁵⁷ An Australian study noted a significant 0.7-week shorter gestation [–1.3, –0.1] among women with blood $25(\text{OH})\text{D}$ levels $<28 \text{ nmol/L}$ compared with those with higher levels.³⁰ A hospital-based study from Japan also found lower

mean 25(OH)D levels among mothers with threatened premature delivery.⁶⁴

Fetal loss

One trial reported a case of stillbirth in the non-intervention arm, but we found no other trials or observational studies of vitamin D intake with data on fetal loss.⁴² One study among HIV-positive women from Tanzania found no significant difference in fetal loss among women with deficiency vs. those with sufficient status (RR = 1.05 [95% CI 0.63, 1.74]).⁴⁹

Pre-eclampsia, caesarian section and maternal mortality

We did not find any published data from trials on the effects of vitamin D supplementation on risk of pre-eclampsia. Preliminary data shared with us by investigators from the trial in South Carolina indicate monotonic reductions in risk with increasing supplement dosage (400, 2000, 4000 IU) for a composite pre-eclampsia/eclampsia/gestational hypertension outcome, which, although not significant in intent-to-treat analysis, became significant after controlling for race (personnal communication, Bruce Hollis, Jan 9, 2012).

Pooled analysis of a very large ($n = 23\,423$) study from Norway and a large ($n = 1718$) study from Massachusetts (Figure S7) revealed no significant difference in risk of pre-eclampsia between top and bottom categories of total vitamin D intake (OR = 0.95 [95% CI 0.86, 1.06]).⁸⁹ While the comparison between >800 IU with <200 IU of total vitamin D intake in the Norwegian study was not statistically significant (OR = 0.89 [0.75, 1.06]), women with intake between 600 and 800 IU had significantly reduced risk of pre-eclampsia (adjusted OR 0.77 [0.61–0.96]) compared with those consuming <200 IU/day. In contrast, a heightened risk of gestational hypertension was associated with increased vitamin D intake in the study from Massachusetts (adjusted OR = 1.11 [1.01, 1.21]).

Observational studies of vitamin D status during pregnancy and risk of pre-eclampsia have not shown consistent associations (Table S5) Investigators of a study from Pittsburgh observed an inverse monotonic dose response relationship between 25(OH)D levels in early pregnancy and pre-eclampsia: for every 50 nmol/L decline in 25(OH)D levels, the risk of

pre-eclampsia more than doubled (adjusted OR 2.4 [1.1, 5.4]).⁶⁵ Similarly, a nested case control study from North Carolina reported that women with 25(OH)D levels <50 nmol/L had more than five times greater risk of severe preeclampsia compared with those with levels >75 nmol/L (adjusted OR 5.41 [2.02, 14.52]).⁶⁶ In contrast, a recent nested case control study conducted in Massachusetts found no statistically significant difference in risk of pre-eclampsia for women with 25(OH)D levels <37.5 nmol/L (adjusted OR 1.35 [0.40, 4.50]).⁶⁷ Another prospective cohort study of pregnancies at high risk for pre-eclampsia in Canada found no effect of 25(OH)D during early pregnancy on pre-eclampsia risk.⁶⁸

In a recently published trial from South Carolina, no statistically significant differences in mode of delivery (caesarian section vs. vaginal delivery) were noted by vitamin D supplementation group, although adjustment for race reportedly led to a statistical significant trend of increasing protection with higher dosage.⁵ An observational study undertaken in Boston found that women with vitamin D levels 25(OH)D < 37.5 nmol/L during pregnancy were found to have nearly a four times greater risk of caesarian delivery (adjusted OR 3.84 [1.71, 8.62]).¹ Similarly no association between maternal vitamin D status and mode of delivery was found in an Australian observational study.⁵⁶

No trials or observational studies of vitamin D supplementation/intake and maternal mortality or morbidity during pregnancy were identified. However, a study from Tanzania found that pregnant women with 25(OH)D levels <80 nmol/L had increased risk of HIV disease progression and that risk of all-cause mortality was significantly lower in the highest quintile of 25(OH)D compared with the lowest (incidence RR = 0.58 [0.40, 0.84]).⁴⁸

Neonatal and infant growth

One supplementation trial in the UK reported significantly greater weight gain among infants born to women supplemented with vitamin D compared with the placebo group at 3, 6, 9 and 12 months of life [12-month comparison: 6.39 vs. 5.92 kg in the control group ($P < 0.01$)].⁶⁹ Up to 6 months of age, there were no differences in attained height between groups, but by 1 year of age, those in the vitamin D group had grown 27.9 vs. 24.6 cm in the placebo group ($P < 0.001$).

A large observational study in the Netherlands found no differences in multivariable adjusted mean weight-for-age *z* scores by category of maternal vitamin D status during pregnancy for any measure taken during the first year of life. While infants born to mothers with 25(OH)D levels <30 nmol/L had significantly lower mean length for age *z* scores at 1 month compared with those born to women adequate status (>50 nmol/L), paradoxically they had higher *z* scores by 12 months with no differences observed at 3, 6 or 9 months.⁵⁷ In another study conducted in the Gambia among a population with high vitamin D status, no significant relationships or trends were found by maternal 25(OH)D status taken at either week 20 or week 36 of pregnancy and weight or height-for-age *z* scores at 2, 13 or 52 weeks.⁴⁷ A cohort study of the effects of maternal vitamin D status during pregnancy on subsequent outcomes in Southampton, UK, found no differences in attained weight or length at 9 months of follow-up across quartiles of 25(OH)D status measured in late pregnancy (with cut points at <30, 50, 75 and >75 nmol/L).⁵⁴ However, in a linear regression model examining predictors of height at 9 months that included height measured at birth, a significant association with maternal 25(OH)D was observed ($P = 0.02$).^{54,70} A study in India found no difference in attained height at age 5 years between children of mothers with 25(OH)D levels above vs. below 50 nmol/L during pregnancy.⁵⁰

Neonatal and infant morbidity and mortality

We did not identify any trials of vitamin D supplementation during pregnancy with outcomes related to infant or child mortality, although a death was noted in one trial.⁴² In a cohort study of 1194 children from Massachusetts, no significant trend was found across quintiles of maternal vitamin D intake during pregnancy on risk of reported diagnosis of respiratory infections by a health professional up to 3 years of age in multivariable adjusted analysis.⁶⁰ A study of 922 infants in New Zealand found significantly greater risk of respiratory infection (a composite variable of colds, cough, whooping cough, chest infections and ear infections) by 3 months of age among infants with cord blood levels of 25(OH)D less than 25 nmol/L in adjusted analysis compared with levels at or above 75 nmol/L (OR = 2.04 [1.13, 3.17]).⁷¹ In contrast to these findings, a cohort study from Southampton,

England, which followed up children at age 9 months, found that mothers in the top quartile of 25(OH)D status in late pregnancy were significantly more likely to report their children having been diagnosed with pneumonia or bronchiolitis, compared with those in the bottom quartile (unadjusted OR 4.80 [1.01, 22.73]), although no differences in risk for respiratory infections overall or for chest infections or bronchitis were observed.⁵⁴ The same study unexpectedly also found that children of mothers in the highest quartile of vitamin D status were more likely to have reported having one or more bouts of diarrhoea vs. those in the bottom quartile (OR = 1.87 [1.01, 3.46]). In a study of infants born to HIV-positive mothers in Tanzania, vitamin D insufficiency during pregnancy (<80 nmol/L) was associated with heightened risk of a composite end-point of infant mortality/HIV infection (RR = 1.49 [1.07, 2.09]).⁴⁹

Comments

Scientific understanding of the importance of vitamin D during pregnancy for perinatal and child health outcomes is growing rapidly, and our review consolidates a great deal of new information from trials and observational studies not incorporated in a prior meta-analysis on the topic.³⁵ In addition to its classical functions related to calcium homeostasis and bone development, emerging evidence suggests that adequate maternal vitamin D status could play important roles in ensuring proper fetal and placental development and proper immune response and function during pregnancy, although the relative importance of its different putative effects on pathways leading to clinical outcomes is not well understood.^{16,22,65}

It is important to interpret the findings of our pooled analyses with caution, particularly given the small number and small sample size of existing trials and the heterogeneity observed across a number of outcomes. Most trials tested the effects of vitamin D supplements provided during the third trimester and in two trials, supplementation did not bring mean levels above 50 nmol/L (Table S6).^{42,51} All trials to date, with the exception of one⁴⁶, were conducted among populations living at northern latitudes with evidence of vitamin D deficiency or insufficiency. The generalizability of findings of these trials to populations living near the equator with potentially greater exposure to sunlight is uncertain, although it is important to consider the role that cultural practices of head covering

and urban lifestyles may have in contributing to vitamin D insufficiency even in tropical countries.

Despite the lack of a statistical significance of the effect observed in our pooled analysis of SGA, we found fairly consistent evidence from trials suggesting that vitamin D has the potential to influence fetal growth among deficient populations, supported by significant effects observed in the meta-analysis of data on gestational weight gain and low birthweight. Our findings suggested either a null or a modest effect on mean birth weight. It is well accepted that mean birthweight is limited in its ability to capture fetal growth restriction, partly because it also reflects gestational age.⁶² Only one observational study suggested that the risk of SGA might increase at higher levels of 25(OH)D, but many studies appeared to only examine 25(OH)D as a dichotomous categorical variable. Future observational studies should examine potential non-linear relationships across the entire distribution.⁶² Further exploration of heterogeneity in effects by race and/or vitamin D receptor genotype may be important.^{58,62}

Some, but not all, studies suggested an effect of vitamin D on risk of pre-eclampsia. In addition to the studies we reviewed, a trial using cod liver oil containing vitamin D along with multi-micronutrient supplement found a significant 32% reduction in preeclampsia risk, and a trial of vitamin D and calcium from India indicated a non-significant benefit on pre-eclampsia.^{72,73} It has been speculated that early pregnancy, when the placenta is still developing, might be the most aetiologically relevant time period for vitamin D supplementation on pre-eclampsia but this hypothesis requires further testing and received limited support from the one observational study to explore the importance of timing of supplementation during pregnancy.⁷⁴

We found little evidence to evaluate the effect of vitamin D on preterm birth or any of its obstetric precursors. Approximately 25–40% of all preterm births are thought to be associated with intra-uterine infection.⁷⁵ An influence of vitamin D status on bacterial infections during pregnancy is plausible and is supported by the consistency of findings of several cross-sectional observational studies in the US suggesting inverse relationships between 25(OH)D and bacterial vaginosis during pregnancy.^{15,76,77} Larger observational studies or trials with more detailed outcome evaluation are needed to assess the potential for vitamin D to influence risk of preterm birth.

Both the observational study from Massachusetts and the trial from South Carolina provide support for an effect of vitamin D on risk of primary caesarean section.^{1,5} In apparent contrast to these findings, two studies excluded from our analysis because of their non-prospective nature suggest no association between mode of delivery or dystocia and maternal vitamin D status.^{78,79} Heterogeneity in these associations is not entirely unexpected because decision making related to caesarian delivery may vary across settings. Given the strength of the association observed in the study from Massachusetts, the role of vitamin D in regulation of calcium (which may help to initiate labour and influence muscle function), and the potential role on pre-eclampsia, further exploration would be worthwhile.⁸⁰

Maternal serum levels of 25(OH)D during pregnancy are correlated with cord blood and neonatal levels of 25(OH)D could influence neonatal and early childhood health and growth, particularly because breastmilk is a poor source of vitamin D in absence of high dose maternal supplementation.⁵ A growing number of studies suggest the importance of adequate vitamin D status during childhood to the prevention of respiratory infections. A study from Ethiopia found that children with rickets had a 13-fold higher risk of pneumonia compared with controls⁵ while a trial in Afghanistan found that vitamin D supplementation of children diagnosed with pneumonia both significantly reduced the risk of repeat episodes during 90 days of follow-up by 22% and increased the time to repeat episode.⁸¹ Limitations of the studies we identified include reliance on maternal reports of doctor's diagnosis, little specificity of outcomes, and in the case of the study from England showing increased risk associated with better vitamin D status, a lack of adjustment for potential confounders such as access to health care or education.⁵⁴ Infections remain an important cause of neonatal and early childhood mortality in many countries, and trials of maternal vitamin D supplementation in such settings should also include follow-up of children for respiratory infections (and HIV seroconversion in high-prevalence settings).^{48,49,82}

The importance of vitamin D to linear growth during childhood was considered at least as early the 1930s.^{83,84} The strongest support for a direct role of vitamin D supplementation on child growth comes from the trial in the UK. Beneficial effects on linear growth were observed at 9 months but not prior to that time.⁶⁹ It is difficult to explain the incon-

sistencies between these findings and observations from the Netherlands showing that children born to vitamin D-deficient mothers appeared to have greater growth velocity, although residual confounding and vitamin D supplementation practices during early childhood in the latter study have been offered as explanations.⁵⁷

Policy implications and future research directions

Despite growing interest in the relationships between vitamin D status during pregnancy and perinatal and infant health outcomes, the epidemiological evidence base remains weak for all of the outcomes we included in our review. Compelling evidence exists for a potential role of vitamin D on a number of perinatal and maternal health outcomes and more randomised trials of vitamin D supplementation during pregnancy are needed to evaluate the potential for vitamin D supplementation to prevent adverse outcomes. Such trials should be undertaken in settings in which vitamin D deficiency is likely to be a risk: latitude, cultural practices of head covering, urban life style, poor dietary intake of vitamin D and season are all factors that may be useful to consider when selecting populations for such trials.

Dosage for such trials should be guided by population 25(OH)D levels at baseline and desired target levels.⁸⁵ The threshold used to define optimal serum 25(OH)D levels is contentious, although many researchers have argued that levels of at least 75–80 nmol or even higher are desirable based on observational studies and estimates of circulating levels from living under UV-rich conditions similar to which humans evolved.^{32,37} Recent research from the multi-dose trial of pregnant women suggests that serum levels of 25(OH)D exceeding 100 nmol/L may be needed to optimise production of 1,25(OH)D.⁵

The fat soluble properties of vitamin D mean that intermittent (e.g. weekly or monthly) dosage is possible, which may be particularly useful in countries with weak health infrastructure, but also raises the need to consider potential adverse effects due to toxicity. The upper limit of intake above which adverse health outcomes such as hypercalcaemia during pregnancy may develop is uncertain. The US tolerable upper limit for women of reproductive age including pregnant women was recently set at 4000 IU/day although it has been argued that there is little evidence of toxicity of higher levels up to 10 000 IU/

day.³³ Dosages administered during recent trials without adverse effects include daily provision of up to 4000 IU/day vitamin D₃ throughout pregnancy in the trial from South Carolina⁵ (although women with high baseline serum levels were excluded from the highest dose group and supplementation began at 16 weeks), provision of a weekly dose of 35 000 IU D₃ during the third trimester in Bangladesh,⁸⁶ and a one time dose of 200 000 IU vitamin D₃ in the third trimester of pregnancy.^{42,51} Monitoring of adverse events in clinical trials using high intermittent dosing may also be an important consideration.⁸⁷

Lastly, we note that the vast majority of studies published to date on vitamin D and perinatal health outcomes have been undertaken in high-income countries. While populations in these settings may be at greater risk for vitamin D deficiency because of lower UV light exposure, more research is needed in populations from low-income countries, which may have lower dietary intake, higher disease burden, and for which vitamin D deficiency may be a growing problem associated with urbanisation.

Conclusion

In a systematic review of the literature we found only a low level of evidence relating vitamin D supplementation or intake during pregnancy on perinatal and infant health-related outcomes. Emerging evidence suggesting plausible effects on intra-uterine growth restriction, pre-eclampsia, and both maternal and infant infections as important outcomes in need of further research in low-income settings. Several trials are underway including in Pakistan and Bangladesh and should help to clarify the importance of vitamin D supplementation as an intervention for perinatal, maternal and infant health outcomes.^{5,88} Vitamin D is an essential nutrient with well-established roles in calcium metabolism and the prevention of rickets that are important for policymakers to consider alongside the outcomes reviewed here.

Acknowledgements

We greatly appreciate the willingness of Dr Christina Yu and Dr Bruce Hollis and Dr Carol Wagner to share additional data for this analysis. Andrew Thorne-Lyman is supported by training grant T32 #DK 007703 from the U.S. National Institutes of Health (NIH) and

a Julius B. Richmond Fellowship from the Center on the Developing Child at Harvard University.

Conflicts of interests

The authors have no conflicts of interest to report related to this article.

References

- Merewood A, Mehta SD, Chen TC, Bauchner H, Holick MF. Association between vitamin D deficiency and primary cesarean section. *Journal of Clinical Endocrinology and Metabolism* 2009; 94:940–945.
- Green H, Pindar D, Davis G, Melanby E. Diet as a prophylactic agent against puerperal sepsis-with special reference to vitamin A as an anti-infective agent. *BMJ (Clinical Research Ed.)* 1931; ii:595–598.
- Chesney RW. Vitamin D and The Magic Mountain: the anti-infectious role of the vitamin. *Journal of Pediatrics* 2010; 156:698–703.
- Prentice A. Vitamin D deficiency: a global perspective. *Nutrition Reviews* 2008; 66:S153–S164.
- Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double blind, randomized clinical trial of safety and effectiveness. *Journal of Bone and Mineral Research* 2011; 26:2341–2357.
- Holick MF. Vitamin D deficiency. *New England Journal of Medicine* 2007; 357:266–281.
- Arabi A, El Rassi R, El-Hajj Fuleihan G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. *Nature Reviews Endocrinology* 2010; 6:550–561.
- Feleke Y, Abdulkadir J, Mshana R, Mekbib TA, Brunvand L, Berg JP, et al. Low levels of serum calcidiol in an African population compared to a North European population. *European Journal of Endocrinology/European Federation of Endocrine Societies* 1999; 141:358–360.
- Farrant HJ, Krishnaveni GV, Hill JC, Boucher BJ, Fisher DJ, Noonan K, et al. Vitamin D insufficiency is common in Indian mothers but is not associated with gestational diabetes or variation in newborn size. *European Journal of Clinical Nutrition* 2009; 63:646–652.
- Kovacs CS. Vitamin D in pregnancy and lactation: maternal, fetal, and neonatal outcomes from human and animal studies. *American Journal of Clinical Nutrition* 2008; 88:520S–528S.
- Henry HL, Norman AW. Vitamin D: metabolism and biological actions. *Annual Review of Nutrition* 1984; 4:493–520.
- WHO (World Health Organization). *Vitamin and Mineral Requirements in Human Nutrition*, 2nd edn. Geneva: WHO, 2004.
- Salle BL, Delvin EE, Lapillonne A, Bishop NJ, Glorieux FH. Perinatal metabolism of vitamin D. *American Journal of Clinical Nutrition* 2000; 71:1317S–1324S.
- Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. *American Journal of Clinical Nutrition* 2004; 80:1752S–1758S.
- Bodnar LM, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. *Journal of Nutrition* 2009; 139:1157–1161.
- Bodnar LM, Simhan HN. Vitamin D may be a link to black–white disparities in adverse birth outcomes. *Obstetrical and Gynecological Survey* 2010; 65:273–284.
- Hewison M. Vitamin D and the immune system. *Journal of Endocrinology* 1992; 132:173–175.
- Evans KN, Bulmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidual function. *Journal of the Society for Gynecologic Investigation* 2004; 11:263–271.
- Walker VP, Modlin RL. The vitamin D connection to pediatric infections and immune function. *Pediatric Research* 2009; 65:106R–113R.
- Misawa Y, Baba A, Ito S, Tanaka M, Shiohara M. Vitamin D(3) induces expression of human cathelicidin antimicrobial peptide 18 in newborns. *International Journal of Hematology* 2009; 90:561–570.
- Bartley J. Vitamin D, innate immunity and upper respiratory tract infection. *Journal of Laryngology and Otolaryngology* 2010; 124:465–469.
- Liu NQ, Kaplan AT, Lagishetty V, Ouyang YB, Ouyang Y, Simmons CF, et al. Vitamin D and the regulation of placental inflammation. *Journal of Immunology* 2011; 186:5968–5974.
- Barrera D, Avila E, Hernandez G, Mendez I, Gonzalez L, Halhali A, et al. Calcitriol affects hCG gene transcription in cultured human syncytiotrophoblasts. *Reproductive Biology and Endocrinology* 2008; 6:3.
- Barrera D, Avila E, Hernandez G, Halhali A, Biruete B, Larrea F, et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. *Journal of Steroid Biochemistry and Molecular Biology* 2007; 103:529–532.
- Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism* 2007; 92:2017–2029.
- Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). *Cell Biochemistry and Function* 2002; 20:227–232.
- Pawley N, Bishop NJ. Prenatal and infant predictors of bone health: the influence of vitamin D. *American Journal of Clinical Nutrition* 2004; 80:1748S–1751S.
- Pasco JA, Wark JD, Carlin JB, Ponsonby AL, Vuillermin PJ, Morley R. Maternal vitamin D in pregnancy may influence not only offspring bone mass but other aspects of musculoskeletal health and adiposity. *Medical Hypotheses* 2008; 71:266–269.
- Giuliani DL, Boland RL. Effects of vitamin D3 metabolites on calcium fluxes in intact chicken skeletal muscle and myoblasts cultured in vitro. *Calcified Tissue International* 1984; 36:200–205.

- 30 Morley R, Carlin JB, Pasco JA, Wark JD. Maternal 25-hydroxyvitamin D and parathyroid hormone concentrations and offspring birth size. *Journal of Clinical Endocrinology and Metabolism* 2006; 91:906–912.
- 31 Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: The National Academies Press, 2011.
- 32 Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. *Journal of Bone and Mineral Research* 2011; 26:455–457.
- 33 Holick MF. Vitamin D: a D-lightful solution for health. *Journal of Investigative Medicine* 2011; 59:872–880.
- 34 Dror DK, Allen LH. Vitamin D inadequacy in pregnancy: biology, outcomes, and interventions. *Nutrition Reviews* 2010; 68:465–477.
- 35 Mahomed K, Gulmezoglu AM. Vitamin D supplementation in pregnancy. *Cochrane Database of Systematic Reviews*. The Cochrane Library 2011, (2):CD000228.
- 36 Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. *American Journal of Clinical Nutrition* 2004; 79:717–726.
- 37 Hollis BW. Vitamin D requirement during pregnancy and lactation. *Journal of Bone and Mineral Research* 2007; 22 (Suppl 2):V39–V44.
- 38 Dawodu A, Wagner CL. Mother–child vitamin D deficiency: an international perspective. *Archives of Disease in Childhood* 2007; 92:737–740.
- 39 Prentice A, Schoenmakers I, Laskey MA, de Bono S, Ginty F, Goldberg GR. Nutrition and bone growth and development. *Proceedings of the Nutrition Society* 2006; 65:348–360.
- 40 The Nordic Cochrane Centre TCC. Review Manager (RevMan) Version 5.1. Copenhagen, 2011.
- 41 Headrick TC. *Statistical Simulation: Power Method Polynomials and Other Transformations*. Boca Raton, FL: Chapman & Hall/CRC, 2010.
- 42 Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S. Vitamin D deficiency and supplementation during pregnancy. *Clinical Endocrinology* 2009; 70:685–690.
- 43 Marya RK, Rathee S, Lata V, Mudgil S. Effects of vitamin D supplementation in pregnancy. *Gynecologic and Obstetric Investigation* 1981; 12:155–161.
- 44 Erkkola M, Kaila M, Nwaru BI, Kronberg-Kippila C, Ahonen S, Nevalainen J, *et al.* Maternal vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children. *Clinical and Experimental Allergy* 2009; 39:875–882.
- 45 Mannion CA, Gray-Donald K, Koski KG. Association of low intake of milk and vitamin D during pregnancy with decreased birth weight. *CMAJ: Canadian Medical Association Journal* 2006; 174:1273–1277.
- 46 Marya RK, Rathee S, Dua V, Sangwan K. Effect of vitamin D supplementation during pregnancy on foetal growth. *Indian Journal of Medical Research* 1988; 88:488–492.
- 47 Prentice A, Jarjou LM, Goldberg GR, Bennett J, Cole TJ, Schoenmakers I. Maternal plasma 25-hydroxyvitamin D concentration and birthweight, growth and bone mineral accretion of Gambian infants. *Acta Paediatrica* 2009; 98:1360–1362.
- 48 Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, *et al.* Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. *PLoS ONE* 2010; 5:e8770.
- 49 Mehta S, Hunter DJ, Mugusi FM, Spiegelman D, Manji KP, Giovannucci EL, *et al.* Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. *Journal of Infectious Diseases* 2009; 200:1022–1030.
- 50 Krishnaveni GV, Veena SR, Winder NR, Hill JC, Noonan K, Boucher BJ, *et al.* Maternal vitamin D status during pregnancy and body composition and cardiovascular risk markers in Indian children: the Mysore Parthenon Study. *American Journal of Clinical Nutrition* 2011; 93:628–635.
- 51 Mallet E, Gugi B, Brunelle P, Henocq A, Basuyau JP, Lemeur H. Vitamin D supplementation in pregnancy: a controlled trial of two methods. *Obstetrics and Gynecology* 1986; 68:300–304.
- 52 Brooke OG, Brown IR, Bone CD, Carter ND, Cleeve HJ, Maxwell JD, *et al.* Vitamin D supplements in pregnant Asian women: effects on calcium status and fetal growth. *BMJ (Clinical Research Ed.)* 1980; 280:751–754.
- 53 Watson PE, McDonald BW. The association of maternal diet and dietary supplement intake in pregnant New Zealand women with infant birthweight. *European Journal of Clinical Nutrition* 2010; 64:184–193.
- 54 Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, *et al.* Maternal vitamin D status during pregnancy and child outcomes. *European Journal of Clinical Nutrition* 2008; 62:68–77.
- 55 Viljakainen HT, Saarnio E, Hytinen T, Miettinen M, Surcel H, Makitie O, *et al.* Maternal vitamin D status determines bone variables in the newborn. *Journal of Clinical Endocrinology and Metabolism* 2010; 95:1749–1757.
- 56 Bowyer L, Catling-Paull C, Diamond T, Homer C, Davis G, Craig ME. Vitamin D, PTH and calcium levels in pregnant women and their neonates. *Clinical Endocrinology* 2009; 70:372–377.
- 57 Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early pregnancy vitamin D status in relation to fetal and neonatal growth: results of the multi-ethnic Amsterdam born children and their development cohort. *British Journal of Nutrition* 2010; 104:108–117.
- 58 Morley R, Carlin JB, Pasco JA, Wark JD, Ponsonby AL. Maternal 25-hydroxyvitamin D concentration and offspring birth size: effect modification by infant VDR genotype. *European Journal of Clinical Nutrition* 2009; 63:802–804.
- 59 Clifton-Bligh RJ, McElduff P, McElduff A. Maternal vitamin D deficiency, ethnicity and gestational diabetes. *Diabetic Medicine* 2008; 25:678–684.
- 60 Camargo CA Jr, Rifas-Shiman SL, Litonjua AA, Rich-Edwards JW, Weiss ST, Gold DR, *et al.* Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. *American Journal of Clinical Nutrition* 2007; 85:788–795.
- 61 Baker PN, Wheeler SJ, Sanders TA, Thomas JE, Hutchinson CJ, Clarke K, *et al.* A prospective study of micronutrient

- status in adolescent pregnancy. *American Journal of Clinical Nutrition* 2009; 89:1114–1124.
- 62 Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, *et al.* Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. *Journal of Nutrition* 2010; 140:999–1006.
- 63 Scholl TO, Chen X. Vitamin D intake during pregnancy: association with maternal characteristics and infant birth weight. *Early Human Development* 2009; 85:231–234.
- 64 Shibata M, Suzuki A, Sekiya T, Sekiguchi S, Asano S, Udagawa Y, *et al.* High prevalence of hypovitaminosis D in pregnant Japanese women with threatened premature delivery. *Journal of Bone and Mineral Metabolism* 2011; 29:615–620.
- 65 Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. *Journal of Clinical Endocrinology and Metabolism* 2007; 92:3517–3522.
- 66 Baker AM, Haeri S, Camargo CA Jr, Espinola JA, Stuebe AM. A nested case–control study of midgestation vitamin D deficiency and risk of severe preeclampsia. *Journal of Clinical Endocrinology and Metabolism* 2010; 95:5105–5109.
- 67 Powe CE, Seely EW, Rana S, Bhan I, Ecker J, Karumanchi SA, *et al.* First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. *Hypertension* 2010; 56:758–763.
- 68 Shand A, Nassar N, Von Dadelszen P, Innis S, Green T. Maternal vitamin D status in pregnancy and adverse pregnancy outcomes in a group at high risk for pre-eclampsia. *BJOG* 2010; 117:1593–1598.
- 69 Brooke OG, Butters F, Wood C. Intrauterine vitamin D nutrition and postnatal growth in Asian infants. *BMJ (Clinical Research Ed.)* 1981; 283:1024.
- 70 Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, *et al.* Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. *Lancet* 2006; 367:36–43.
- 71 Camargo CA Jr, Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, *et al.* Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. *Pediatrics* 2011; 127:e180–e187.
- 72 Olsen SF, Secher NJ. A possible preventive effect of low-dose fish oil on early delivery and pre-eclampsia: indications from a 50-year-old controlled trial. *British Journal of Nutrition* 1990; 64:599–609.
- 73 Marya RK, Rathee S, Manrow M. Effect of calcium and vitamin D supplementation on toxemia of pregnancy. *Gynecologic and Obstetric Investigation* 1987; 24:38–42.
- 74 Haugen M, Brantsaeter AL, Trogstad L, Alexander J, Roth C, Magnus P, *et al.* Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. *Epidemiology* 2009; 20:720–726.
- 75 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet* 2008; 371:75–84.
- 76 Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *American Journal of Obstetrics and Gynecology* 2003; 189:139–147.
- 77 Davis LM, Chang SC, Mancini J, Nathanson MS, Witter FR, O'Brien KO. Vitamin D insufficiency is prevalent among pregnant African American adolescents. *Journal of Pediatric and Adolescent Gynecology* 2010; 23:45–52.
- 78 Mandic Havelka A, Yektaei-Karin E, Hulthenby K, Sorensen OE, Lundahl J, Berggren V, *et al.* Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level. *Acta Paediatrica* 2010; 99:836–841.
- 79 Brunvand L, Shah SS, Bergstrom S, Haug E. Vitamin D deficiency in pregnancy is not associated with obstructed labor. A study among Pakistani women in Karachi. *Acta Obstetrica Gynecologica Scandinavica* 1998; 77:303–306.
- 80 Holick MF. Vitamin D: the other steroid hormone for muscle function and strength. *Menopause* 2009; 16:1077–1078.
- 81 Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D, *et al.* Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. *Tropical Medicine and International Health* 2010; 15:1148–1155.
- 82 Villamor E. A potential role for vitamin D on HIV infection? *Nutrition Reviews* 2006; 64:226–233.
- 83 Hypponen E, Fararouei M, Sovio U, Hartikainen AL, Pouta A, Robertson C, *et al.* High-dose vitamin d supplements are not associated with linear growth in a large Finnish cohort. *Journal of Nutrition* 2011; 141:843–848.
- 84 Stearns G, Jeans P, Vandecar V. The effect of vitamin D on linear growth in infancy. *Journal of Pediatrics* 1936; 9:1–10.
- 85 Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *American Journal of Clinical Nutrition* 2003; 77:204–210.
- 86 Roth D, Al-Mahmud A, Arifeen SE, Raqib R, Black R, Baqui A. *Randomized Pilot Trial of Two Oral Vitamin D3 Supplementation Regimens during the Third Trimester of Pregnancy in Bangladeshi Women: Effects on Neonatal Vitamin D Status and Safety*. Denver: Pediatric Academic Societies and Asian Society for Pediatric Research, 2011.
- 87 Roth DE. Vitamin D supplementation during pregnancy: safety considerations in the design and interpretation of clinical trials. *Journal of Perinatology* 2011; 31:449–459.
- 88 (NIH) USNIoH. Clinicaltrials.gov. 2011; <http://clinicaltrials.gov/ct2/results?term=vitamin+D+pregnancy> [last accessed May 2012].
- 89 Oken E, Ning Y, Rifas-Shiman SL, Rich-Edwards JW, Olsen SF, Gillman MW. Diet during pregnancy and risk of preeclampsia or gestational hypertension. *Annals of Epidemiology* 2007; 17:663–668.
- 90 Shand AW, Nassar N, Von Dadelszen P, Innis SM, Green TJ. Maternal vitamin D status in pregnancy and adverse pregnancy outcomes in a group at high risk for pre-eclampsia. *BJOG* 2010; 117:1593–1598.
- 91 Maxwell JD, Ang L, Brooke OG, Brown IR. Vitamin D supplements enhance weight gain and nutritional status in pregnant Asians. *British Journal of Obstetrics and Gynaecology* 1981; 88:987–991.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Trials and observational studies of vitamin D supplementation and mean birthweight (in grams).

Figure S2. Trials of vitamin D supplementation and SGA and low birthweight, disaggregated by dosing approach.

Figure S3. Trials of vitamin D supplementation and mean crown–heel length (in cm).

Figure S4. Trials of vitamin D supplementation and mean daily weight gain during the 3rd trimester (in grams).

Figure S5. Supplementation and preterm delivery and mean duration of gestation, disaggregated by dosing approach.

Figure S6. Observational studies of vitamin D intake and mean gestational age.

Figure S7. Observational studies of vitamin D intake and pre-eclampsia risk.

Table S1. Search strategy and keywords.

Table S2. Evaluation of the quality of eligible trials for potential inclusion in the meta-analysis.

Table S3. Evaluation of the quality of evidence of individual observational studies for potential inclusion in the meta-analysis.

Table S4. Prospective observational studies of the relationship between maternal blood levels of 25(OH)D during pregnancy and measures of fetal growth, birth weight, and preterm birth.

Table S5. Prospective observational studies of the relationship between maternal blood levels of 25(OH)D during pregnancy and pre-eclampsia.

Table S6. Baseline and attained levels of maternal 25(OH)D at delivery in trials.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.